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UK.Chromogranin A (CgA), a neuroactive glycoprotein, is associated with microglial activation cascades
implicated in neurodegeneration. Here we show that CgA-dependent inducible nitric oxide synthase
(iNOS) expression and stress responses in microglia involved signalling via scavenger receptors (SR),
since SR class-A (SR-A) ligands blocked iNOS expression, mitochondrial depolarisation, apoptosis
and glutamate release. Furthermore, block of SR-A ameliorated CgA-induced microglial neurotox-
icity. In contrast, block of CD36, or the receptor for advanced glycation end products (RAGE) did
not prevent CgA-induced microglial activation and neurotoxicity. Thus, manipulation of speciﬁc
scavenger receptor-coupled signalling pathways may provide avenues for therapeutic intervention
in neurodegenerative diseases implicating microglial activation with chromogranin peptides.
Crown Copyright  2009 Published by Elsevier B.V. on behalf of Federation of European Biochemical
society. All rights reserved.1. Introduction
The glycoprotein CgA is implicated in neurodegeneration in
Alzheimer’s (AD), stroke, Parkinson’s, Pick’s and prion disease
[1–4]. Chromogranins can mediate secretion of mutant super oxide
dismutase proteins linked to amyotrophic lateral sclerosis [5].
Microglial activation is involved in the degenerative processes of
many neurological conditions [6] and suppression of the microglial
response may decrease the development and impact of neuroin-
ﬂammation and neurodegeneration [6]. CgA is a potent activator
of microglia [7,8], inducing their production of potential neurotox-
ins [7,9] and activating microglial stress pathways [7,9,10].
Here, we show that CgA can signal in microglia via scavenger
receptors (SR), and the neurotoxicity of CgA-exposed microglia
can be prevented through the inhibition of SR-A. SR are upregu-
lated in microglia around senile plaques in AD tissue [11] and,
in vitro , amyloid-beta peptides act as SR ligands [12–15]. Thus
processes which modulate the interaction of CgA with SR may have
therapeutic potential in neurodegenerative diseases where microg-
lial activation is implicated.d by Elsevier B.V. on behalf of Fede
k).
entre for Neurodegenerative
enmark Hill, London SE5 8AF,2. Materials and methods
2.1. Animals and materials
Wistar rats were bred and reared in house from stock animals
originally purchased from Charles River UK Ltd. (Kent, UK). Foetal
calf serum (FCS), and Dulbecco’s modiﬁed Eagle’s medium (D-
MEM) were obtained from Invitrogen (Paisley, UK). Synthetic CgA
was purchased from Scientiﬁc Marketing Associates, Hertfordshire,
UK (from the Peptide Institute, Japan) and was veriﬁed endotoxin-
free. Neutralising antibody against RAGE was a kind gift from Dr.
Larry Denner (Texas Biotechnology Corporation, TX, USA). Neutral-
ising antibody against SR-A (clone 2F8) was from Serotec (Kidling-
ton, Oxford, UK). Mouse anti-CD36/SMø neutralising monoclonal
antibody and ﬂuorescein isothiocyanate-annexin V (annexin V)
was from Autogen Bioclear (Calne, Wiltshire, UK). 5,50,6,60-Tetra-
ethylbenzimidazole carbo-cyanine iodide (JC-1) was from Molecu-
lar Probes (Leiden, The Netherlands). Poly-inosine, fucoidan and all
other reagents were from Sigma (Dorset, UK).
2.2. Preparation and treatment of cell cultures
Primary cultures of rat microglia and cerebellar granule neurons
(CGC) were prepared and maintained as previously described
[7,16]. The BV-2 microglia cell line, kindly provided by Dr. S.F.
Tzeng (Department of Life Sciences, National Cheng Kung
University, Taiwan), was cultured in D-MEM plus 10% FCS, 2 mMration of European Biochemical society. All rights reserved.
3462 C. Hooper et al. / FEBS Letters 583 (2009) 3461–3466glutamine, 44 mM NaHCO3, 100 U/ml penicillin, 100 lg/ml
streptomycin and 125 lg/l amphotericin B. Microglia were
pre-incubated with poly-inosine (0.1 or 0.5 lg/ml), or fucoidan
(50 or 200 lg/ml; a complex sulphated polysaccharide found in
brown seaweed), both of which are inhibitory ligands of SR-A
[15] for 1 h before the addition of CgA (100 nM). Alternatively,
microglia were pre-incubated with neutralising antibodies against
RAGE (200 or 400 lg/ml) [17], SR-A (10–100 lg/ml) [18], or CD36
(SMø) (1 or 10 lg/ml) [13], for 1 h before the addition of CgA
(100 nM). Following activation, microglial-conditioned medium
(MGCM) was collected, added to CGC cultures at a 1:1 ratio with
CGC medium and incubated for a further 24 h before analysis.iNOS
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Fig. 1. Block of SR but not RAGE inhibits CgA-induced microglial reactivity. (A)
Poly-inosine blocks CgA-induced iNOS expression. Western blot of iNOS and b-actin
in microglia treated with 100 nM CgA ± poly-inosine (i: 0.1 lg/ml; ii: 0.5 lg/ml),
neutralising RAGE antibody (i: 200 lg/ml; ii: 400 lg/ml) or with inhibitors alone
(iii: 0.5 lg/ml poly-inosine or 400 lg/ml neutralising RAGE antibody) for 24 h.
‘‘Basal” is untreated microglia at 24 h. (B) Poly-inosine blocks CgA-induced nitrite
production. Total nitrite levels in culture medium from microglia treated as in A or
with 100 lg/ml anti-SR-A antibody, measured with Griess reagent. ***P < 0.001 or
*P < 0.05 versus basal. (C) Poly-inosine blocks CgA-induced ERK phosphorylation.
Western blot of anti-phospho-ERK or total-ERK in (a) primary microglia 3 h after
treatment with 100 nM CgA or together with poly-inosine (i: 0.1 lg/ml; ii: 0.5 lg/
ml), with poly-inosine alone (0.5 lg/ml) (iii) or in untreated cells (Basal). (b) Control
lysates from microglia treated for 4 or 24 h with poly-inosine (0.5 lg/ml). (D) Poly-
inosine blocks CgA-induced glutamate release. Glutamate in MGCM from primary
microglia treated with 100 nM CgA ± 0.5 lg/ml poly-inosine, 200 lg/ml fucoidan or
400 lg/ml neutralising RAGE antibody for 24 h. ‘‘Basal” indicated MGCM from
microglia untreated for 24 h. Units describe nmoles of glutamate per lg of
microglial protein per ml of medium. ***P < 0.001 versus basal.2.3. Measurement of mitochondrial depolarisation, apoptosis and cell
death
Mitochondrial depolarisation was assessed using JC-1 [9,10].
Apoptosis and cell death were assessed in unﬁxed cells
using 20[epoxyphenyl]-5-[4-methyl-1-piperazinyl]-2,50-bi-1H-
benzimidazol Hoechst 33342 (Hoechst 33342) for total cell num-
ber and pyknotic nuclei, in conjunction with propidium iodide
(PI) [19] for dead cells or annexin V [9] for exterior staining of
phosphatidylserine [20]. Cell counts were performed on at least
ﬁve ﬁelds per coverslip, three coverslips per treatment from three
independent experiments.
2.4. Immuno-blotting
Immuno-blotting was performed using standard procedures
with 1:5000 rabbit anti-iNOS (BD Biosciences Pharmingen, Oxford,
UK) or 1:750 mouse anti-phospho-extracellular signal regulated
kinase (p-ERK; Autogen Bioclear, Wiltshire, UK) and ECL
(Amersham Pharmacia, Buckinghamshire, UK). Protein loading
controls used were 1:1000 mouse anti-b-actin (Sigma, UK) or
1:500 rabbit anti-total ERK (Autogen Bioclear, Wiltshire, UK),
respectively. Immunoblots are representative of three independent
experiments.
2.5. Measurement of nitrite and glutamate production
Total nitrite levels in MGCM were determined using Griess re-
agent [7]. Glutamate was measured using ﬂuorometric quantiﬁca-
tion of NADPH, produced through the reaction of glutamate with
NADP+ in the presence of glutamate dehydrogenase [9,21].
2.6. Statistics
To compare two or more treatments with a control group (or
other treatment) a one-way analysis of variance (ANOVA) was used
followed by a Tukey post test. P values < 0.05 were considered sta-
tistically signiﬁcant, and P < 0.05*, <0.005**, <0.001***.A
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Fig. 2. Block of CD36 does not prevent CgA-induced iNOS expression or glutamate
release. (A) Anti-CD36/SMø does not block CgA- induced iNOS expression. Western
blot of iNOS and b-actin in primary microglia incubated with 1 or 10 lg/ml anti-
CD36/SMø in the absence (Basal) or presence of 100 nM CgA for 24 h. (B) Anti-
CD36/SMø does not block CgA-induced glutamate release. Glutamate in MGCM
from BV-2 microglia treated with 100 nM CgA ± 10 lg/ml anti-CD36/SMø after 24 h.
Units describe nmoles of glutamate per lg of microglial protein per ml of medium.
***P < 0.001 versus basal condition.
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3.1. SR modulate microglial CgA-induced signalling
Consistent with previous ﬁndings, CgA triggered iNOS expres-
sion after 24 h [7,10], which was completely inhibited by poly-ino-
sine (Fig. 1A), but not by neutralising anti-RAGE (Fig. 1A). Similarly,
poly-inosine, or neutralizing anti-SR-A (100 lg/ml) but not
neutralising anti-RAGE inhibited CgA-induced nitrite productionB
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10 lg/ml anti-CD36/SMø with or without CgA for 24 h. The number of cells displaying los
of condensed nuclei) were counted. ***P < 0.001, **P < 0.005 versus basal.(Fig. 1B). Basal nitrite production was found to be 2 ± 0.001 lM.
None of the inhibitors/antibodies affected basal responses
(Fig. 1A and B).
CgA-evoked ERK phosphorylation, which peaks at 3 h and
triggers iNOS expression [9], was abolished by poly-inosine
(Fig. 1Ca). This inhibitor did not affect basal ERK phosphorylation
at 3 h (Fig. 1Caiii), 4 or 24 h (Fig. 1Cb). CgA-induced glutamate re-
lease from microglia [7], which is linked to stress responses in
these cells [22], was blocked by poly-inosine or fucoidan, but notPoly-I
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Fig. 4. Block of SR inhibits CgA-induced microglial neurotoxicity. Cell death in CGC neuronal cultures exposed for 24 h to medium from BV-2 microglia incubated for 24 h
with 200 lg/ml fucoidan, 0.5 lg/ml poly-inosine (B) or 1 or 10 lg/ml anti-CD36/SMø blocking antibody (C) with or without CgA (100 nM). Basal conditions (Ai), CgA (Aii),
CgA + poly-inosine (Aiii) CgA + fucoidan (Aiv) stained with annexin V-FITC (green cells) or propidium iodide (red cells). Neurons were assessed for total cell numbers (Hoechst
33342 staining), cell death (propidium iodide-positive; ﬁlled bars) or for cells displaying externally exposed phosphatidylserine (annexin-V-FITC-positive; white bars) (B, C).
In some experiments, conditioned medium from BV-2 microglia was added to CGC cultures together with direct addition of fucoidan, poly-inosine, or Anti-CD36 SMø
(+direct). ***P < 0.001, **P < 0.005, *P < 0.05 versus basal.
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anti-C36/SMø did not prevent CgA-induced iNOS expression
(Fig. 2A) or glutamate release (Fig. 2B; or at 100 lg/ml, data not
shown).
3.2. SR modulate CgA-induced microglial stress
CgA-exposed primary microglia undergo nitric oxide-depen-
dent cell death, mediated by mitochondrial depolarisation [7,10].
In conﬁrmation of this, CgA-exposed BV-2 microglia underwentmitochondrial depolarisation and apoptosis (Fig. 3A), which was
signiﬁcantly attenuated by poly-inosine or fucoidan (Fig. 3B) but
not by block of CD36 (Fig. 3B) or RAGE (data not shown).
3.3. SR modulate CgA-induced microglial neurotoxicity
CgA-activated microglia become neurotoxic [7,8,17]. As previ-
ously demonstrated with primary microglia, exposure of BV-2
microglia to CgA led to soluble neurotoxin production, which pro-
moted neuronal death (indicated by increased annexin V-FITC and
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Fig. 5. (A) Proposed intracellular signalling cascades elicited in microglia by CgA acting via SR to induce ERK phosphorylation and expression of iNOS, mitochondrial stress,
release of glutamate and soluble neurotoxins and ultimately microglial apoptosis and neuronal death based on current and previous work by the authors for the effects of CgA
on microglia [7,9,10,19]. (B) CgA comprises 457 amino acids, a high proportion of which are consecutive negatively charged glutamic acid residues (ﬁlled).
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(Fig. 4A and B). Poly-inosine or fucoidan (Fig. 4B), but not anti-
CD36/SMø (Fig. 4C), completely attenuated CgA-induced neuronal
apoptosis and death, suggesting that activation of SR-A, but not
CD36, on microglia contributes to the neurotoxicity of CgA-stimu-
lated microglia.4. Discussion
Here we report that SR-A mediates CgA-induced activation of
microglia through the phosphorylation of ERK leading to iNOS
expression; upstream signals include the Src kinase-dependent
activation of MEK [9] (Fig. 5A). Furthermore, SR-A mediates CgA-
induced mitochondrial depolarisation and apoptosis in microglia.
CgA-dependent apoptosis in microglia is due to iNOS activity and
occurs via a caspase-1 mediated pathway [7,10], resulting in mem-
brane phosphatidylserine ﬂip and ultimately cell death [9]
(Fig. 5A). Similarly, CgA-evoked release of microglial glutamate,
which occurs predominantly via activation of the Xc- transporter
[7], probably as a result of cellular requirements for glutathione
synthesis [20], can also be prevented by SR-A block. CgA-evoked
microglial glutamate release can lead to direct neurotoxicity [7]
or activation of microglial metabotropic glutamate receptors, in
particular mGlu2, fuelling microglial cell stress and neurotoxicity
by inducing microglial TNFa and Fas-ligand shedding [19]
(Fig. 5A). Blocking RAGE or CD36 did not attenuate CgA-induced
microglial responses, suggesting that these receptors play no role.
Interestingly these results show that in CNS derived microglia
rather than peripheral macrophages (and macrophages after prim-
ing), the SR-A ligands do not stimulate microglial responses per se,
highlighting major differences between the signalling response inmicroglia compared with peripheral macrophages and probably
reﬂecting the overall heightened activation state of peripheral
macrophages [23–26].
In summary, CgA-triggered microglial responses can occur via
SR-dependent mechanisms, most likely a member of the SR-A fam-
ily (Fig. 5A) and targeting these receptors can modulate CgA-in-
duced neurotoxicity. CgA comprises a high proportion of
consecutive negatively charged glutamic acid residues (Fig. 5B)
which are a recognised structural feature of SR ligands. Thus, native
LDL does not function as an SR ligand, whereas acetylated and oxi-
dised LDL exhibit a high afﬁnity for SR [23]. Eliminating SR-A
expression in mice can signiﬁcantly reduce atherosclerosis [27],
indicating that the reduction of inﬂammatory cascades via this
receptor can be beneﬁcial. Microglia show plastic expression of
SR, particularly following activation [11–15]. Further experiments
will allow us to determine whether other subclasses of SR receptor
are involved, such as SR-MARCO. Manipulation of SR-coupled sig-
nalling pathways in microglia may provide avenues for therapeutic
intervention in neuroinﬂammatory diseases in which CgA-depen-
dent mechanisms of microglial activation are implicated.
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